President Donald Trump’s pick for U.S. drug czar withdrew after it become public that he spearheaded a bill that undercut the government’s power to crack down on opioid makers that were flooding the market with the addictive painkillers.

Shares of AcelRx Pharmaceuticals plunged more than 60 percent after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

Despite the death of one patient, bluebird bio’s Lenti-D gene therapy treatment for patients with cerebral adrenoleukodystrophy (CALD) could be a viable option for treating the potentially fatal genetic disease, researchers said.

Shares of Sarepta Therapeutics recovered from a dip of about 8 percent as investors seem to have rallied behind the company’s Duchenne muscular dystrophy (DMD) drug Exondys 51.

Drug developer Axovant Sciences Ltd. said it would stop testing the company’s lead drug in Alzheimer’s after it failed to meet the main goals of a late-stage trial.

People who exercise five days a week for 30 minutes significantly reduce their risk of dying early and of developing heart disease, even if a sports club or gym is not an option, according to a new international study.

Two Roche drugs were placed on partial clinical hold as the U.S. FDA continues to examine potential dangers of checkpoint inhibitors following deaths associated with Merck’s Keytruda.

New Mexico sued eight opioid manufacturers and wholesale distributors, becoming the latest state or local government to file a lawsuit seeking to hold corporations accountable for a national drug addiction epidemic.

Drug maker Servier and the French drug regulator will face trial over weight-loss pill Mediator, believed to have caused at least 500 deaths in one of France’s worst health scandals, the prosecutor’s office said.

South Carolina sued Purdue Pharma, accusing the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic.